Tolcapone in stable Parkinson's disease: Efficacy and safety of long- term treatment

Neurology

Volumn 49, Issue 3, 1997, Pages 665-671

  Waters, C H ^a,g   Kurth, M ^b   Bailey, P ^c   Shulman, L M ^d   LeWitt, P ^e   Dorflinger, E ^f   Deptula, D ^f   Pedder, S ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

^c SAINT JOHN REGIONAL HOSPITAL   (Canada)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e Sinai Clin Neurosci Res Center   (United States)

^f HOFFMANN LA ROCHE INC   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; PLACEBO; TOLCAPONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; ENZYME ACTIVITY; HUMAN; MAJOR CLINICAL STUDY; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; TREATMENT PLANNING;

EID: 0030833203     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.3.665     Document Type: Article

References (20)

1. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-1027.
2. Männistö PT, Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 1990;66:317-323.
3. Marsden CD. Parkinson's disease. Lancet 1990;335:948-952.
4. Tolosa ES, Valldeoriola F, Martí MJ. New and emerging strategies for improving levodopa treatment. Neurology 1994; 44(suppl. 6):S35-S44.
5. Sharman D. The metabolism of catecholamines. Br Med Bull 1973;20:110-115.
6. LeWitt PA. Treatment strategies for extension of levodopa effect. Neurol Clin 1992;10:511-526.
7. Mouradian MM, Chase TN. Levodopa response fluctuations in Parkinson's disease. Clin Neuropharmacol 1988;11:378-385.
8. Fahn S. Adverse effects of levodopa in Parkinson's disease. In: Calne DB, ed. Drugs for the treatment of Parkinson's disease. Berlin, Germany: Springer-Verlag, 1989:385-409.
9. Männistö PT. Clinical potential of catechol-O-methyl-transferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs 1994;1:172-179.
10. Zürcher G, Dingemanse J, Da Prada M. Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G, eds. New developments in therapy of Parkinson's disease. Rome, Italy: John Libbey, 1991:37-43.
11. Dingemanse J, Jorga K, Zürcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-262.
12. Anonymous. Levodopa. In: Dollery C, ed. Therapeutic drugs. Edinburgh: Churchill Livingstone, 1991:L10-L15.
13. Myllylä W, and the Tolcapone in PD Study Group I (TIPS). Clinical efficacy of tolcapone in L-dopa-treated parkinsonian patients with 'wearing-off' phenomenon: a multicenter double-blind study [abstract]. Neurology 1995;45:A276.
14. Kurth MC, Adler CH, Saint Hilaire M, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997;48:81-87.
15. Dupont E, Burgunder J-M, Findley LJ, Olsson J-E, Dorflinger E, Tolcapone in Parkinson's Disease Study Group II (TIPS II). Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Mov Disord 1997 (in press).
16. Waters CH, Kurth MC, Shulman L, et al. Evaluation of the efficacy and safety of tolcapone (Tasmar) in Parkinson's disease patients with a stable response to levodopa [abstract]. Neurology 1996;46:A160.
17. Limousin P, Pollak P, Pfefen JP, Tournier-Gervason CL, Dubuis R, Perret JE. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol 1995;18:258-265.
18. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993;43:2685-2688.
19. Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995;57:508-517.
20. Dingemanse J, Jorga K, Zürcher G, et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996; 50:47-55.